Dr. Neil Goldenberg serves as Overall Principal Investigator for an NIH-Sponsored multinational phase 3 randomized controlled trial on the duration of anticoagulant therapy for venous thromboembolism in patients <21 years of age. He also is associate dean for research at Johns Hopkins All Children’s Hospital, chief research officer of the Johns Hopkins All Children’s Hospital Research Institute, and director of the Johns Hopkins All Children’s Institute for Clinical and Translational Research. His research focuses on pediatric thrombosis and stroke.
After receiving his medical degree from McGill University Faculty of Medicine in Montréal, Dr. Goldenberg completed his internship and residency at the University of South Florida College of Medicine as a member of the inaugural class of the combined residency program in internal medicine and pediatrics. He performed a fellowship in pediatric hematology/oncology/bone marrow transplant at The Children’s Hospital, Denver (now Children’s Hospital Colorado), and the University of Colorado Health Sciences Center, where he also earned a Ph.D. in clinical investigation.
Prior to joining Johns Hopkins in 2012, Dr. Goldenberg was on the faculty of the University of Colorado School of Medicine and served as director of the Children’s Clinical Research Organization and co-director of the Pediatric Thrombosis and Stroke Programs at Children’s Hospital Colorado. He also served as director of the Department of Clinical Science and Safety at CPC Clinical Research, a non-profit clinical trials management organization affiliated with the University of Colorado, after having served as director of Clinical Research for the Mountain States Regional Hemophilia and Thrombosis Center.
Dr. Goldenberg received the Eberhard E. Mammen Award for Excellence in Hemostasis and Thrombosis in 2012. In 2016, Dr. Goldenberg received a U01 grant award from the National Institutes of Health, National Heart Lung and Blood Institute for the Kids-DOTT multinational randomized clinical trial designed to inform the future standard of care on duration of anticoagulant therapy for provoked venous thromboembolism in patients under 21 years of age. This trial involves over 50 participating centers in the U.S., Canada, Europe, and Australia, with the Clinical Coordinating Center and Central Biorepository located at Johns Hopkins All Children’s Hospital, and the Data Coordinating Center located at the University of Colorado and CPC Clinical Research.
Dr. Goldenberg is the Pediatric Subcommittee chair of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis and is a member of the ASH Clinical Trials Subcommittee and a Distinguished Faculty of the ASH Clinical Research Training Institute (CRTI). In addition, he has co-authored clinical guidelines in venous thromboembolic disease from the American Heart Association, American College of Chest Physicians, and ISTH SSC and was a pediatric representative to the Surgeon General’s Workshops on Deep Vein Thrombosis Surveillance (co-sponsored by the Centers for Disease Control). He has been a reviewer for Lancet, Lancet Oncology, Pediatrics, Blood, and other journals, and speaks nationally on coagulation disorders, stroke, and clinical research methods.